# SMPD1

## Overview
The SMPD1 gene encodes the enzyme acid sphingomyelinase (ASM), a crucial component of sphingolipid metabolism. ASM is a lysosomal hydrolase that catalyzes the breakdown of sphingomyelin into ceramide and phosphocholine, playing a vital role in maintaining cellular lipid homeostasis and membrane integrity (Kornhuber2015Secretory; Jenkins2009Roles). The enzyme is categorized as a metallophosphoesterase, characterized by its dependence on zinc ions for catalytic activity (Gorelik2016Crystal). ASM is involved in various cellular processes, including apoptosis, inflammation, and pathogen response, through its regulation of ceramide, a bioactive lipid with significant signaling properties (Jenkins2009Roles; Breiden2021Acid). Mutations in the SMPD1 gene can lead to acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease types A and B, which are lysosomal storage disorders with diverse clinical manifestations (Geberhiwot2023Consensus; Zampieri2015SMPD1).

## Structure
The SMPD1 gene encodes the enzyme acid sphingomyelinase (ASM), which plays a crucial role in sphingolipid metabolism. The molecular structure of ASM includes several distinct domains and structural features. The enzyme comprises an N-terminal saposin domain, a proline-rich linker, a catalytic metallophosphatase domain, and a helical C-terminal domain (Zhou2016Human). The saposin domain is unique to ASM and undergoes conformational changes in response to lipid binding, stabilized by disulfide bonds (Zhou2016Human). 

The catalytic domain of ASM belongs to the calcineurin-like phosphoesterase family and contains a two-zinc ion center crucial for its enzymatic activity (Gorelik2016Crystal). This domain is characterized by a core of two six-stranded mixed beta-sheets surrounded by eight alpha-helices, with an additional C-terminal subdomain composed of four alpha-helices (Gorelik2016Crystal). The active site involves zinc-activated water molecules and key residues such as His280 and His317 (Gorelik2016Crystal).

Post-translational modifications include glycosylation at five N-glycosylation sites, which may influence the enzyme's stability and function (Gorelik2016Crystal). The enzyme's structure is essential for its function in hydrolyzing sphingomyelin into ceramide and phosphocholine, with zinc ions playing a pivotal role in substrate specificity and activation (Zhou2016Human).

## Function
The SMPD1 gene encodes the enzyme acid sphingomyelinase (ASM), which plays a crucial role in sphingolipid metabolism by catalyzing the hydrolysis of sphingomyelin into ceramide and phosphocholine. This process is essential for maintaining cellular lipid homeostasis and membrane integrity (Kornhuber2015Secretory; Jenkins2009Roles). ASM exists in two forms: lysosomal ASM (L-ASM) and secretory ASM (S-ASM). L-ASM functions within the lysosome, while S-ASM operates extracellularly and requires Zn2+ ions for activation (Kornhuber2015Secretory).

In healthy human cells, ASM is involved in various cellular processes, including apoptosis, senescence, differentiation, and inflammation, through the regulated generation of ceramide, a bioactive lipid with signaling properties (Jenkins2009Roles). The enzyme is synthesized in the endoplasmic reticulum and undergoes glycosylation, which is crucial for its proper folding, trafficking, and function (Jenkins2009Roles). ASM activity is also sensitive to reducing agents due to its disulfide bonds (Jenkins2009Roles).

ASM is expressed in various tissues, including the central nervous system, heart, pancreas, thyroid, and kidneys, indicating its significant role in the development and function of these organs (Wang2023SMPD1). Proper ASM function is vital for preventing the toxic accumulation of sphingomyelin, supporting normal cellular and organ function (Wang2023SMPD1).

## Clinical Significance
Mutations in the SMPD1 gene are responsible for acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease types A and B (NPD A and NPD B). These are autosomal recessive lysosomal storage disorders characterized by the accumulation of sphingomyelin in lysosomes due to deficient activity of acid sphingomyelinase (ASM) (Geberhiwot2023Consensus; Zampieri2015SMPD1). Type A is a severe neurodegenerative disorder with early mortality, while Type B is a non-neuronopathic form with visceral symptoms and a heterogeneous clinical course (Desnick2010Identification; Zampieri2015SMPD1).

The SMPD1 gene is located on chromosome 11p15.4 and consists of six exons. Over 250 variants have been identified, including missense, nonsense, frameshift mutations, and splicing abnormalities (Pinto2021Acid; Geberhiwot2023Consensus). Specific mutations, such as p.R610del, are associated with the attenuated NPB phenotype, while others like p.L304P and p.R498L are linked to the severe NPA phenotype (Pinto2021Acid; Zampieri2015SMPD1).

Alterations in SMPD1 expression can impact various organs, including the liver, spleen, and brain, due to its high expression in these tissues. This dysfunction can lead to significant clinical manifestations, including hepatosplenomegaly and neurological symptoms (Wang2023SMPD1). Understanding the genotype-phenotype correlations is crucial for diagnosing and managing ASMD (Wang2023SMPD1).

## Interactions
The SMPD1 gene encodes the enzyme acid sphingomyelinase (ASM), which is involved in the hydrolysis of sphingomyelin into ceramide and phosphorylcholine. This enzyme participates in various interactions that are crucial for its function and regulation. ASM interacts with zinc ions, which are essential for its enzymatic activity, particularly in the catalytic domain where zinc coordination is crucial for substrate hydrolysis (Zhou2016Human). The enzyme's activity is also influenced by its interaction with phosphocholine, which is necessary for its activation (Zhou2016Human).

ASM is involved in the formation of ceramide-rich platforms in the plasma membrane, which facilitate the transport of membrane proteins and signaling molecules. This interaction is significant in processes such as cell death, proliferation, and differentiation (Li2020Crosstalk). The enzyme also interacts with various signaling pathways, including the ASM-ROS-NLRP3 inflammasome axis, which is important for maintaining endothelial cell integrity and is implicated in tissue injury and fibrosis (Li2020Crosstalk).

ASM's interactions extend to its role in pathogen internalization and immune response, affecting infections by bacteria, fungi, and viruses. It is involved in the internalization and killing of pathogens like Staphylococcus aureus and Chlamydia trachomatis (Breiden2021Acid). These interactions highlight the enzyme's multifaceted role in cellular processes and its potential therapeutic implications.


## References


[1. (Kornhuber2015Secretory) Johannes Kornhuber, Cosima Rhein, Christian P. Müller, and Christiane Mühle. Secretory sphingomyelinase in health and disease. Biological Chemistry, 396(6–7):707–736, June 2015. URL: http://dx.doi.org/10.1515/hsz-2015-0109, doi:10.1515/hsz-2015-0109. This article has 111 citations and is from a peer-reviewed journal.](https://doi.org/10.1515/hsz-2015-0109)

[2. (Breiden2021Acid) Bernadette Breiden and Konrad Sandhoff. Acid sphingomyelinase, a lysosomal and secretory phospholipase c, is key for cellular phospholipid catabolism. International Journal of Molecular Sciences, 22(16):9001, August 2021. URL: http://dx.doi.org/10.3390/ijms22169001, doi:10.3390/ijms22169001. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms22169001)

[3. (Wang2023SMPD1) Ruisong Wang, Ziyi Qin, Long Huang, Huiling Luo, Han Peng, Xinyu Zhou, Zhixiang Zhao, Mingyao Liu, Pinhong Yang, and Tieliu Shi. Smpd1 expression profile and mutation landscape help decipher genotype–phenotype association and precision diagnosis for acid sphingomyelinase deficiency. Hereditas, March 2023. URL: http://dx.doi.org/10.1186/s41065-023-00272-1, doi:10.1186/s41065-023-00272-1. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s41065-023-00272-1)

[4. (Li2020Crosstalk) Cao Li, Shanshan Guo, Wenyuan Pang, and Zhigang Zhao. Crosstalk between acid sphingomyelinase and inflammasome signaling and their emerging roles in tissue injury and fibrosis. Frontiers in Cell and Developmental Biology, January 2020. URL: http://dx.doi.org/10.3389/fcell.2019.00378, doi:10.3389/fcell.2019.00378. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2019.00378)

[5. (Jenkins2009Roles) Russell W. Jenkins, Daniel Canals, and Yusuf A. Hannun. Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cellular Signalling, 21(6):836–846, June 2009. URL: http://dx.doi.org/10.1016/j.cellsig.2009.01.026, doi:10.1016/j.cellsig.2009.01.026. This article has 222 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellsig.2009.01.026)

[6. (Geberhiwot2023Consensus) Tarekegn Geberhiwot, Melissa Wasserstein, Subadra Wanninayake, Shaun Christopher Bolton, Andrea Dardis, Anna Lehman, Olivier Lidove, Charlotte Dawson, Roberto Giugliani, Jackie Imrie, Justin Hopkin, James Green, Daniel de Vicente Corbeira, Shyam Madathil, Eugen Mengel, Fatih Ezgü, Magali Pettazzoni, Barbara Sjouke, Carla Hollak, Marie T. Vanier, Margaret McGovern, and Edward Schuchman. Consensus clinical management guidelines for acid sphingomyelinase deficiency (niemann–pick disease types a, b and a/b). Orphanet Journal of Rare Diseases, April 2023. URL: http://dx.doi.org/10.1186/s13023-023-02686-6, doi:10.1186/s13023-023-02686-6. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13023-023-02686-6)

[7. (Zhou2016Human) Yan-Feng Zhou, Matthew C. Metcalf, Scott C. Garman, Tim Edmunds, Huawei Qiu, and Ronnie R. Wei. Human acid sphingomyelinase structures provide insight to molecular basis of niemann–pick disease. Nature Communications, October 2016. URL: http://dx.doi.org/10.1038/ncomms13082, doi:10.1038/ncomms13082. This article has 44 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms13082)

[8. (Pinto2021Acid) Carolina Pinto, Diana Sousa, Vladimir Ghilas, Andrea Dardis, Maurizio Scarpa, and Maria Macedo. Acid sphingomyelinase deficiency: a clinical and immunological perspective. International Journal of Molecular Sciences, 22(23):12870, November 2021. URL: http://dx.doi.org/10.3390/ijms222312870, doi:10.3390/ijms222312870. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms222312870)

[9. (Desnick2010Identification) Jonathan P. Desnick, Jungmin Kim, Xingxuan He, Melissa P. Wasserstein, Calogera M. Simonaro, and Edward H. Schuchman. Identification and characterization of eight novel smpd1 mutations causing types a and b niemann-pick disease. Molecular Medicine, 16(7–8):316–321, April 2010. URL: http://dx.doi.org/10.2119/molmed.2010.00017, doi:10.2119/molmed.2010.00017. This article has 36 citations and is from a peer-reviewed journal.](https://doi.org/10.2119/molmed.2010.00017)

[10. (Gorelik2016Crystal) Alexei Gorelik, Katalin Illes, Leonhard X. Heinz, Giulio Superti-Furga, and Bhushan Nagar. Crystal structure of mammalian acid sphingomyelinase. Nature Communications, July 2016. URL: http://dx.doi.org/10.1038/ncomms12196, doi:10.1038/ncomms12196. This article has 76 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms12196)

[11. (Zampieri2015SMPD1) Stefania Zampieri, Mirella Filocamo, Annalisa Pianta, Susanna Lualdi, Laura Gort, Maria Jose Coll, Richard Sinnott, Tarekegn Geberhiwot, Bruno Bembi, and Andrea Dardis. Smpd1 mutation update: database and comprehensive analysis of published and novel variants: human mutation. Human Mutation, 37(2):139–147, December 2015. URL: http://dx.doi.org/10.1002/humu.22923, doi:10.1002/humu.22923. This article has 70 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.22923)